The global biologics market, representing a class of medications derived from living organisms, is on the cusp of unprecedented growth. A recent analysis forecasts the industry to expand at a remarkable compound annual growth rate (CAGR) of 8.5%, surging to a staggering US$ 817.48 billion by 2032. This monumental development underscores the transformative potential of …